Rebecca Coll


Dr Rebecca Coll



PostDoctoral Researcher, Inflammasome Lab
UQ Fellow




Rebecca completed her PhD research under Prof. Luke O’Neill in Trinity College Dublin at one of the leading laboratories in the innate immunity field. For her work on the regulation of TLR signalling she received the International Endotoxin and Innate Immunity Society Young Investigator Award in 2012. However, her main research focus has been inflammasomes and their therapeutic targeting by small molecule drugs. Her recent first author publication on MCC950 in Nature Medicine has been widely acclaimed (the subject of seven commentaries in leading journals and attention from 24 international news outlets) and is already a highly cited paper. She joined the Schroder group in May 2014 with the goal of defining the molecular target of MCC950 as part of a broader collaboration between the Schroder, Cooper and O’Neill labs.


Research is what I'm doing when I don't know what I'm doing.

Wernher von Braun





Office Telephone: +61 7 3346 2351

Lab Telephone: +61 7 3346 2071


Institute for Molecular Bioscience

Google Scholar

Research Gate

Researcher ID







2017 Australasian Society for Immunology Postdoctoral International Travel Award, to attend the Keystone Symposium on Cell Death and Inflammation in Dublin, Ireland.


2016 Research Australia Discovery Award.


2016 University of Queensland Fellowship, Academic Level A, Research-Industry, Defining the mechanism of action of MCC950, a small-molecule inhibitor of NLRP3 for the treatment of inflammatory diseases, 2016-2019.


2016 Travel Bursary from the Australasian Society for Immunology, to attend the International Congress of Immunology, Melbourne, Australia.


2016 Competitive placement, including travel costs, for the 5th Network of Immunology Frontiers Winter School on Advanced Immunology in Japan.


2015 Ian Potter Foundation Travel Grant awarded to attend the 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases in Dresden, Germany, 3 September- 3 October 2015, as an Invited Speaker.


2015 Travel Award received from the International Cytokine & Interferon Society (ICIS) to attend and present at the 2014 Meeting of the ICIS in Melbourne, Australia, October 26-29.


2014 Co-investigator, Australia–India Strategic Research Fund Research Grant, Novel immunomodulatory agents for type II diabetes through targeting the NLRP3 inflammasome cascade. Investigators: MA Cooper, RV Jayathirtha, L O’Neill, A Robertson, S Mamidyala, S Kantevari, R Coll.


2013 Travel grant awarded to attend and present at the IL-1-mediated Inflammation and Diabetes: From Basic Science to Clinical Applications Meeting, Nijmegen, The Netherlands, 10-11 October 2013.


2012 International Endotoxin and Innate Immunity Society (IEIIS) Young Investigator Award 2012. Received in recognition of outstanding research achievements.


2012 Travel grant to attend and present at the IEIIS2012 Homeostatic Inflammation Symposium, Tokyo, Japan 23-26 October 2012.




2012  PhD, Trinity College Dublin, School of Biochemistry and Immunology. Advisor: Prof. Luke O’Neill.


2007  BA (Mod), Trinity College Dublin, Biochemistry with Cell Biology (First Class Honours). Advisor: Prof. Andrew Bowie.



17 November 2016, Young immunologist awarded for impact, UQ News
Dr Rebecca Coll, a postdoc from the Inflammasome Lab, has been awarded the prestigous Research Australia Discovery Award for 2016, at the Research Australia Health and Medical Research Awards ceremony in Sydney. Rebecca received the award for her discovery of promising anti-inflammatory compounds that block the NLRP3 inflammasome. She hopes that these compounds will be used to treat patients with inflammatory disease. “I am absolutely thrilled to receive this award and feel that it recognises our fantastic collaboration between chemistry and biology which has driven this innovative research,” Dr Coll said.
UQ News article
Inflammasome Lab article



12 September 2016, UQ’s work on inflammatory disease treatment wins $22m global investment, UQ News
Research from the Inflammasome Lab performed by Dr Rebecca Coll and Dr Kate Schroder, in collaboration with Dr Avril Robertson and Professor Matt Cooper (IMB), and Professor Luke O’Neill's team (Trinity College Dublin), has attracted investment for a new start-up company to develop treatments for inflammatory disorders including Parkinson’s disease and asthma.  The €15 million (A$22 million) investment, co-led by two top global life science investment firms, Novartis Venture Fund and Fountain Healthcare Partners, is one of the largest biotech Series A investments for intellectual property originating from an Australian university.
UQ News article


February 2015, Scientists uncover marvel molecule that could lead to treatments for inflammatory disease
Rebecca Coll and the UQ teams led by Dr Kate Schroder and Prof Matt Cooper, together with their collaborators from the Trinity College Dublin, uncovered a marvel molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new non-invasive treatments for arthritis, multiple sclerosis and Muckle-Wells syndrome, among a myriad of other inflammatory diseases. In the study published in the world’s leading preclinical medical journal Nature Medicine, the researchers showed how the molecule MCC950 can suppress the NLRP3 inflammasome, which is an activator of the key process in inflammatory diseases.

Currently 24 international news articles and 4 scientific blogs have been written about the discovery including those in; The Journal (Ireland), Science Newsline, redOrbit, Today Topics, Medical News Today, The Medical News, Health Medicine Network, Business Standard, Drug Discovery and Development, Tech Times, Health Canal, MedicalXpress, Innovations Report, Science Daily, EurekAlert!, Bioportfolio and more.
See the article metrics at Nature Medicine
Read the full list of news articles

Comment in:
Inflammasome inhibition: putting out the fire. Cell Metabolism
Inflammasome: starving inflammation. Nature Reviews Drug Discovery
Potent small molecule extinguishes the NLRP3 inflammasome. Nature Reviews Rheumatology
The Nlrp3 inflammasome admits defeat. Trends in Immunology
Inflammasome: starving inflammation. Nature Reviews Immunology
Targeting neuroinflammation through inhibition of NLRP3. Nature Reviews Neurology
Taming the Inflammasome. Nature Medicine



Hill JR, Coll RC, Sue N, Reid JC, Dou J, Holley CL, Pelingon R, Dickinson JB, Biden TJ, Schroder K, Cooper MA, Robertson AAB. (2017).
Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors. Chem Med Chem Sep 7;12(17):1449-1457. Pubmed


Bezbradica JS1, Coll R1, Schroder K (2017).
Sterile signals generate weaker and delayed macrophage NLRP3 inflammasome responses relative to microbial signals. Cellular & Molecular Immunology. 14:118-126. 1Joint contribution. Pubmed


Coll R, O'Neill L, Schroder K (2016).
Questions and Controversies in innate immune research: What is the physiological role of NLRP3? Cell Death Discovery Apr 4;2:16019. Cell Death Discovery


Coll RC, Robertson AAB, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Núñez G, Latz E, Kastner DL, Mills KHG, Masters SL, Schroder K, Cooper MA, O’Neill LAJ (2015).
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine 21(3):248-55. Pubmed

See Nature Medicine for a complete list of citations, reviews and media attention this publication has recieved. Read the news articles here

Comment in:
Inflammasome inhibition: putting out the fire. Cell Metabolism
Inflammasome: starving inflammation. Nature Reviews Drug Discovery
Potent small molecule extinguishes the NLRP3 inflammasome. Nature Reviews Rheumatology
The Nlrp3 inflammasome admits defeat. Trends in Immunology
Inflammasome: starving inflammation. Nature Reviews Immunology
Targeting neuroinflammation through inhibition of NLRP3. Nature Reviews Neurology
Taming the Inflammasome. Nature Medicine




Hughes MM, Lavrencic P, Coll RC, Ve T, Ryan DG, Williams NC, Menon D, Mansell A, Board PG, Mobli M, Kobe B, O'Neill LAJ (2017).
Solution structure of the TLR adaptor MAL/TIRAP reveals an intact BB loop and supports MAL Cys91 glutathionylation for signaling. Proceedings of the National Academy of Science U S A Aug 8; 114(32):E6480-E6489. Pubmed


Domingo-Fernández R, Coll RC, Kearney J, Breit S, O'Neill LAJ (2017).
The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1β transcription and activate the NLRP3 inflammasome. Journal of Biological Chemistry Jul 21;292(29):12077-12087. Pubmed


Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF (2016).
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood Dec 22;128(25):2960-2975. Pubmed


Arbore G, West EE, Spolski R, Robertson AAB, Klos A, Rheinheimer C, Dutow P, Woodruff TM, Yu ZX, O'Neill LA, Coll RC, Sher A, Leonard WJ, Köhl J, Monk P, Cooper MA, Arno M, Afzali B, Lachmann HJ, Cope AP, Mayer-Barber KD, Kemper C (2016).
T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 T cells. Science Jun 17;352(6292):aad1210. doi: 10.1126/science.aad1210. Pubmed


Greenhill CJ, Jones GW, Nowell MA, Newton Z, Harvey AK, Moideen AN, Collins FL, Bloom AC, Coll RC, Robertson AA, Cooper MA, Rosas M, Taylor PR, O'Neill LA, Humphreys IR, Williams AS, Jones SA (2014).
Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research & Therapy Aug 30;16(4):419. Pubmed


Finucane OM, Lyons CL, Murphy AM, Reynolds CM, Klinger R, Healy NP, Cooke AA, Coll RC, McAllan L, Nilaweera KN, O'Reilly ME, Tierney AC, Morine MJ, Alcala-Diaz JF, Lopez-Miranda J, O'Connor DP, O'Neill LA, McGillicuddy FC, Roche HM (2015).
Monounsaturated Fatty Acid-Enriched High-Fat Diets Impede Adipose NLRP3 Inflammasome-Mediated IL-1β Secretion and Insulin Resistance Despite Obesity. Diabetes 64(6):2116-2128. Pubmed


Menon D1, Coll RC1, O’Neill LA, Board PG (2014).
Glutathione transferase Omega 1 is required for the lipopolysaccharide-stimulated induction of NADPH oxidase 1 and the production of reactive oxygen species in macrophages. Free Radical Biology & Medicine 73C:318-327. 1Equal contribution


Haneklaus M, O'Neill LA and Coll RC (2013).
Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Current Opinion in Immunology 25(1):40-5.Pubmed


Coll RC, O'Neill LA (2011).
The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes. PLoS One 6(12):e29539. Pubmed


Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, Mullooly N, Mielke LA, Harris J, Coll RC, Mills KH, Mok KH, Newsholme P, Nuñez G, Yodoi J, Kahn SE, Lavelle EC, O'Neill LA (2010).
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nature Immunology 11(10):897-904. Pubmed


Coll RC, O'Neill LA (2010).
New insights into the regulation of signalling by toll-like receptors and nod-like receptors. Journal of Innate Immunity 2(5):406-21. Pubmed




2. O'Neill LA, Coll RC, Cooper MA, Robertson AAB, Schroder K. MacLeod AM, Miller DJ (2017).
Sulfonylureas and related compounds and use of same. PCT/EP2017/053498, Filing: 16/02/2017.


1. O'Neill LA, Coll RC, Cooper MA, Robertson AAB, Schroder K (2016).
Sulfonylureas and related compounds and use of same. PCT/AU2016/050103, Filing: 16/02/2016.